A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
154actual
Sites
44
Countries
Canada, Russia, South Korea +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-03-16 | actual | When the study began enrolling |
| Primary completion | 2020-10-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2018-03-09 | actual | When this record first appeared on the registry |
| Results posted | 2022-10-26 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Urinary Bladder Neoplasms
Interventions
- Drug: Durvalumab
- Drug: Olaparib
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival (PFS)
measured Assessments performed at baseline and every 8 weeks from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), assessed up to the data cut-off date (15 Oct 2020), up to a max. of 31 months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2021-07-09 · 3.2 MB · Prot_000.pdf
Statistical Analysis Planposted 2019-10-04 · 745 KB · SAP_001.pdf
Publications
- PMID 35737919 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed